Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
We share a report about a 24-year-old with hemophilia B who recently received gene therapy in California.
An associate professor living with Hereditary Angioedema encourages fellow patients to “never give up and try to persist in y…
We share a report about a 32-year-old with hemophilia B who recently received gene therapy at Harvard-affiliated Brigham and …
Upwards of 300,000 European patients depend on plasma-derived medicinal products (PDMPs). Policies under consideration could …
Primary immune deficiency is a group of rare diseases that makes people vulnerable to frequent and hard-to-treat infections.
Get an update on CSL’s commitment to sustainability and where we are prioritizing action.
We’re addressing unmet medical needs through new research partnerships with eight world-class researchers.
Antti Kourula, CSL Behring’s Vice President of Commercial Development for Hematology, recently traveled to the Central Asian …
We share reports about a 57-year-old and 63-year-old with hemophilia B who recently received gene therapy.
Americas
Asia Pacific
Middle East
Europe
